Alzamend Neuro Inc Ordinary Shares ALZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
-
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
-
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Trading Information
- Previous Close Price
- $1.34
- Day Range
- $1.31–1.43
- 52-Week Range
- $0.84–2.68
- Bid/Ask
- $1.31 / $1.44
- Shares Outstanding
- 4.83M
- Market Cap
- $6.32M
- Volume/Avg
- 17,032 / 86,927
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.alzamend.com
Valuation
|
Metric
|
ALZN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALZN
|
|---|---|
Quick Ratio | 0.53 |
Current Ratio | 1.31 |
Interest Coverage | −1,324.50 |
Quick Ratio
ALZN
Profitability
|
Metric
|
ALZN
|
|---|---|
Return on Assets (Normalized) | −160.17% |
Return on Equity (Normalized) | −226.57% |
Return on Invested Capital (Normalized) | −226.44% |
Return on Assets
ALZN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>Dq%V&@ | LOCK|>cc&N | $129B | |||
| Moderna Inc
MRNA
| LOCK|sh>GJC | LOCK|Y@ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<#j!F?$ | LOCK|#q?<# | $77B | |||
| argenx SE ADR
ARGX
| LOCK|qh?Vq%% | LOCK|gp | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|VYqF&Q$ | LOCK|Z$l | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hf$R$! | LOCK|^!jr@ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|L#?Y$Vl | LOCK|f^CB@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|HT@%>S$ | LOCK|DM | $24B | |||
| Incyte Corp
INCY
| LOCK|?w<>NfP | LOCK|y#! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|N%H!c%% | LOCK|^ng | $14B |
United States